Pathogenetic and clinical aspects of interleukin 17 blockade in spondylitis
https://doi.org/10.33667/2078-5631-2020-15-5-9
Abstract
This article presents analysis of current data highlighted the problem of pathogenic mechanism of the most common spondyloarthritides (SpA) and focused on the pivotal role of interleukin‑17 in immune inflammation realization. Contribution of IL‑17 in mechanism of SpA particularly in different organ damage, in perpetuation of chronic inflammation and in structural progression is discussed. The clinical and experimental evidence of close relationship between IL‑17A levels, on one hand, and disease activity, high tempo of joint and bone affection as well as SpA extra-articular manifestations, on the other, are presented. Contribution of cell-mediated immune response including activated IL‑17A-producing cells to the pathogenesis of different SpA phenotypes is shown. Great attention is paid to the clinical effects of IL‑17A inhibition in Sp A. The results of clinical trials of novel IL‑17A inhibitor netakimab in the treatment of ankylosing spondylitis are presented. These data have demonstrated high efficacy and safety of tried preparation used in the regimen 120 mg per 2 weeks. On the basis of performed analysis the key role of IL‑17 in SpA pathogenesis is confirmed and expediency of SpA target therapy with novel IL‑17A inhibitor netakimab is justified.
About the Authors
A. R. Babaeva
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
E. V. Kalinina
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
M. S. Zvonorenko
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
I. V. Kostryukova
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
A. L. Emelyanova
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
References
1. Коротаева Т.В. Перспектива применения ингибиторов интерлейкина 17 – нового класса препаратов для таргетной терапии псориатического артрита // Научно-практическая ревматология. 2016. 54 (3). С. 1–9.
2. Насонов Е. Л. Новые возможности фармакотерапии иммуновоспалительных заболеваний: фокус на ингибиторы интерлейкина17 // Научно-практическая ревматология.2017. 55 (1). С. 68–86.
3. Эрдес Ш. Ф. Интерлейкин 17А – новая мишень антицитокиновой терапии анкилозирующего спондилита // Научно-практическая ревматология. 2016. 54 (1). С. 60–66.
4. Эрдес Ш., Насонов Е., Кундер Е. и соавт. / Первичная эффективность нового ингибитора интерлейкина 17 нетакимаба в лечении активного анкилозирующего спондилита у взрослых // Clinical and Experimental Rheumatology, 2019. p. 1–10.
5. Эрдес Ш., Мазуров В.И., Дубинина Т. В. и соавт. / Эффективность и безопасность оригинального ингибитора интерлейкина 17А в лечении пациентов с активным анкилозирующим спондилитом – результаты основного (BCD 085–3 / AILAS) и продленного (BCD 085– 3ext / AILAS-II) клинического исследования II фазы. // Научно-практическая ревматология. 2019, 57 (6): 668–677.
6. Bridgewood C et al. Identification of myeloid cells in the human enthesis as the main source of local IL23 production // Ann Rheum Dis, 2019, 78: 929–933.
7. Cambre I et al. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis // Nat Commun. 2018, 9.
8. Campbell JJ et al. IL 17-Secreting γδT are completely dependent upon CCR for homing to inflamed skin // Ji 2017, 199: 3129–36.
9. Gaidukova I., Mazurov V., Erdes Sh., et al. Netakimab improves patient-related outcomes in patients with radiological axial spondyloarthritis: results from randomized phase III trial (ASTERA) // annrheumdis 2019-eular6/91. FRI0391.
10. Gossec L et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update // Ann Rheum Dis 2015. 0: 1–12.
11. Gravallese EM, Schett G Effects of the IL23-IL17 pathway on bone in spondyloarthritis // Nat Rev Rheumatol, 2018, 14: 631–40.
12. Jo S et al. IL17A induces osteoblast differentiation by activating JAK2/STAT3 in ankilosing spondylitis // Arthritis Res Ther 2019, 20.
13. Lee YH, Song GG Association between interleukin 23R polymorphism and ankylosing spondylitis susceptibility: an updated meta-analysis // Z Rheumatol 2019. 76: 272–80.
14. McGonagle DG et al. The role of IL 17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies // Ann Rheum Dis 2019. 78: 1167–1178.
15. McInnes IB et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from FUTURE 2 study // Arthritis Res Ther 2018, 20.
16. Nossent JC et al. IL23R gene variants in relation to IL17A levels and clinical phenotype in patients with ankylosing spondylitis // Rheumat Adv Pract 2018, 2.
17. Schreiber S et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: retrospective analysis of pooled data from 21 clinical trials // Ann Rheum Dis 2019, 78: 473–9.
18. Smolen JS, Schols M, Braun J et al. Treating axial spondyloarthritisand peripheral spondyloarthritis, especially psoriatic arthritis to target: 2017 update of recommendations by international task force // Ann Rheum Dis 2018. 77: 3–17.
19. Sun C et al. IL17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of pro-inflammatory cytokines // Mol Med Rep 2017, 15: 89–96.
20. Van der Heijde D, Ramiro S, Landewe R et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis // Ann Rheum Dis 2017. 0: 1–14.
21. Van Tok MN et al. Interleukin 17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis // Arthritis Rheumatol. 2019, 71: 612–25.
22. Xueyi L et al. Levels of circulating TH17 cells and regulatory cells in ankylosing spondylitis patients with inadequate response to anti-TNFα therapy / J Clin Immunol 2013, 33: 151–61.
Review
For citations:
Babaeva A.R., Kalinina E.V., Zvonorenko M.S., Kostryukova I.V., Emelyanova A.L. Pathogenetic and clinical aspects of interleukin 17 blockade in spondylitis. Medical alphabet. 2020;(15 (2020)):5-9. (In Russ.) https://doi.org/10.33667/2078-5631-2020-15-5-9
Views:
581
Email this article 